Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Rachel L. HensonAnne M. Fagan

Abstract

Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late-onset AD (LOAD) and autosomal-dominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS. CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho-tau181 (p-tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase-3-like protein 1 (YKL-40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal-associated protein 25 (SNAP-25), and visinin-like protein 1 (VILIP-1) were assessed in CSF from 44 adults with DS from the Alzheimer's Biomarker Consortium-Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene (APOE) ε4 carrier status. Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers. The profile of many established and emerging CSF biomarkers of AD in a cohort of adults with DS was similar to that reported in LOAD and ADAD, wh...Continue Reading

References

Apr 1, 1997·Journal of Intellectual Disability Research : JIDR·E H AylwardA Dalton
Aug 2, 2003·Annals of Neurology·Pau PastorAlison M Goate
Feb 27, 2010·Annals of Neurology·John C MorrisMark A Mintun
Nov 3, 2010·Biological Psychiatry·Rebecca Craig-SchapiroDavid M Holtzman
Aug 9, 2011·Annals of Neurology·Rawan TarawnehDavid M Holtzman
Apr 23, 2013·Journal of Alzheimer's Disease : JAD·Ane KorffUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Jun 15, 2014·Neurology·Davis C RymanUNKNOWN Dominantly Inherited Alzheimer Network
Jul 6, 2014·Neuro-degenerative Diseases·Erik PorteliusNiklas Mattsson
Dec 2, 2015·Molecular Psychiatry·J I VélezM Arcos-Burgos
Mar 29, 2016·JAMA Neurology·Rawan TarawnehDavid M Holtzman
Aug 19, 2016·EMBO Molecular Medicine·Niklas MattssonUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Dec 16, 2016·Science Translational Medicine·Marc Suárez-CalvetUNKNOWN Dominantly Inherited Alzheimer Network
Dec 18, 2016·Clinical Chemistry·Daniel L CrimminsJack H Ladenson
Apr 18, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Alain D DekkerPeter P De Deyn
Jul 25, 2017·Neurology and Therapy·Ni-Chung LeeWuh-Liang Hwu
Dec 6, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Jennifer G GoldmanUn Jung Kang
Mar 28, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Courtney L SutphenUNKNOWN ADNI
Aug 26, 2018·Neuroscience Letters·Shanshan WangUNKNOWN for Alzheimer’s Disease Neuroimaging Initiative
Sep 16, 2018·Neurology·Eric McDadeUNKNOWN Dominantly Inherited Alzheimer Network
Nov 28, 2018·Acta Neuropathologica Communications·Daniel TwohigUNKNOWN Dominantly Inherited Alzheimer Network (DIAN)
Nov 30, 2018·Acta Neuropathologica·José Luis MolinuevoKaj Blennow
Feb 9, 2019·Nature Reviews. Neurology·Ira T Lott, Elizabeth Head
Mar 9, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Suzanne E SchindlerUNKNOWN Dominantly Inherited Alzheimer Network

❮ Previous
Next ❯

Citations

Aug 28, 2021·Journal of Clinical Medicine·Laia Montoliu-GayaNicholas James Ashton

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
ELISAs
ELISA

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Alain D DekkerPeter P De Deyn
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Suzanne E SchindlerDominantly Inherited Alzheimer Network
© 2021 Meta ULC. All rights reserved